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1. Introduction 
Psoriasis is a chronic immune-mediated skin disease with a intricate pathogenesis and a 
strong genetic background (Nickoloff et al., 2007a), that affects approximately 1–3% of the 
worldwide population, with an equal sex distribution (Stern  et al., 2004). The main type of 
psoriasis is chronic plaque psoriasis (Cpp) accounting for approximately 85–90% of all cases. 
The Cpp is characterized by erythematous scaly plaques, usually on elbows, knees, scalp 
and buttocks. Plaque size can diverge from minimal to the involvement of the entire skin 
surface (erythrodermic psoriasis) (C. E. Griffiths et al., 2007; Nestle et al., 2009). Other forms 
of psoriasis comprise guttate psoriasis, inverse, palmoplantar and  generalized pustular 
psoriasis (C. E. Griffiths & Barker, 2007; Nestle et al., 2009). 
The concept of psoriasis as “the disease of healthy people” has long been surpassed,  
nowadays we know that during the time course of this disease, as a consequence of 
dysregulated immunity and ensuing inflammation, certain conditions may appear at 
somewhat unpredictable time points in a progressive fashion;  these so-called co-
morbidities, although targeting different organs, share common pathogenetic factors. They 
often become manifest years after the onset of skin manifestations and are often observed in 
severe forms of psoriasis. 
Psoriatic Arthritis (PsA) is traditionally included among common co-morbidities, even if it 
should be rather considered a component of the clinical spectrum of psoriatic disease. PsA 
involves peripheral joints, the axial skeleton, sacroiliac joints, nails and enthuses, and is 
frequently associated with psoriatic skin lesions. The prevalence of PsA ranges from 5 to 
40% among psoriatic patients lesions (D. D. Gladman, 2009; Nograles et al., 2009).  
Recently, co-morbidities like cardiovascular disease, obesity and metabolic syndrome have 
been found to be associated with psoriasis, raising the idea that psoriasis might not be only a 
skin disorder (Gerdes & Mrowietz, 2009; Kimball et al., 2008a; Menter et al., 2008). 
Psoriasis patients suffer also from considerable psychological and financial burdens 
resulting in a significantly impaired quality of life (Rapp, et al., 1999); likewise traditional 
systemic psoriasis therapies (methotrexate [MTX], cyclosporin A, retinoids or PUVA 
therapy) have a potential for long-term toxicity and cannot always provide plenty disease 
improvement (Pathirana et al., 2009; Smith  et al., 2009). Thus, the development of agents 
efficiently targeting key steps in the pathogenesis of psoriasis and co-morbidities is clearly 
an important goal. 
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2. Pathogenesis 
Psoriasis is thought to be a complex condition  resultant by  a combination of genetic and 
environmental factors. The acute forms of psoriasis, guttate and generalized pustular 
psoriasis (von Zumbusch psoriasis), are both associated with infections (typically b-
haemolytic streptococcal or a viral infection). Other triggering factors which may elicit 
psoriasis in predisposed individuals include trauma (Koebner phenomen) (Eyre & G. G. 
Krueger, 1984), HIV infection (Reveille et al., 1990), psychogenic stress (Gupta et al., 1989) 
and definite drugs (e.g. lithium, beta-blockers, interferons and high dose corticosteroids) 
(Abel et al., 1986).  
Histological examination of psoriatic plaques reveals hyperproliferation of keratinocytes 
(Kcs) with parakeratosis, increased angiogenesis and dermal infiltration of immune cells, 
predominantly T cells, neutrophils, macrophages and dendritic cells (DCs) (Figure 1) 
(Nestle et al., 2009; Nickoloff et al. 2007b).  
 
Fig. 1. Psoriatic skin lesions evolution. Different stimuli (e.g. infections, etc.) can trigger an 
initial episode of psoriasis in genetically predisposed individuals. After starting, the earliest 
events driving the inflammatory eruption are the secretion of INF- from pDCs (plasmacytoid 
dendritic cells) and the production of TNF- by immune cells of both innate and adaptive 
response. Large amounts of IFN- induce activation of the local immune effector cells that 
secrete pro-inflammatory cytokines. TNF- is a very active cytokine of the inflammatory 
infiltrate and is principally secreted by activated macrophages (M), dermal DCs, 
keratinocytes and T cells. The elevated levels of TNF- lead to the maturation of DCs into 
forceful APCs (antigen presenting cells) and, with other cytokines, up-regulates the expression 
of endothelial E-selectin and ICAM-1 attracting further CLA+ T cells in the skin. Also, the 
panel of cytokines released by T cells contributes to the stimulation of epidermal keratinocytes 
and is at least, in some measure, responsible for typical psoriasis skin changes. They induce the 
expression of ICAM-1, CD40 and MHC-II and trigger keratinocyte hyper-proliferation.  
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The increased dermis vascularity is driven by angiogenic factors, such as VEGF (vascular 
endothelial growth factor ), highly present in psoriasis plaques (Detmar et al., 1994). Also,  
the interaction between VEGF and the angiopoietin/Tie signaling pathway is modulated by 
TNF-a (Tumour necrosis factor-a), that together with interleukin 12 (IL-12) and IL-23 are 
well known to be crucial immunological mediators in psoriasis. (Holash et al., 1999; Kuroda 
et al., 2001). Whereas IL-12 induces Th1 (T helper 1) differentiation and thus increases the 
production of TNF-a, IL-23 stimulates primarily Th17 cells, which secrete most importantly 
pro-inflammatory cytokines such as IL-17 and IL-22 (Nestle et al., 2009; Toichi et al., 2006; 
Torti & Feldman, 2007). 
Increased concentrations of TNF-a and IL-12/IL-23 have been found as in psoriatic skin 
(Nestle et al., 2009) as in the synovial fluid and tissue of patients with PsA (FitzGerald & 
Winchester , 2009; Ritchlin et al, 1998). Their role in psoriasis genesis  is highlighted by the 
successful treatment of psoriasis by agents blocking these cytokines (Boker et al., 2007; 
Mössner et al., 2008; Scalon et al., 2009). In addition, polymorphisms of IL-23 receptor gene 
and gene encoding the shared p40 subunit of IL-12 and IL-23 have been linked to psoriasis 
development (Elder et al., 2010; Hüffmaier  et al., 2009; Nestle et al., 2009). 
3. Genetics of psoriasis 
Family studies have shown that psoriasis has a strong genetic component although the 
inheritance pattern is still unclear. 71 % of patients with childhood psoriasis have a positive 
family history (Morris et al., 2001) and  analysis of concordance rates in twin studies show a 
threefold increased risk of psoriasis in monozygotic twins compared to dizygotic twins 
(Brandrup et al., 1978; Pisani & Ruocco, 1984).  
At least ten chromosomal loci have been identified showing statistically significant evidence  
for linkage to psoriasis (PSORS 1-10). However, the only region that has consistently been 
identified in genetic screens of families with psoriasis is the major-histocompatibility 
complex (MHC) region on chromosome 6 named PSORS1 (Capon et al., 2008; Nair et al., 
2006), that is responsible for up to 50 % of genetic susceptibility to psoriasis. Within PSORS1 
the human leukocyte antigen-C (HLA-C) gene which is the strongest candidate gene for 
psoriasis ,  precisely its allele HLACw6 (HLA-Cw*0602) the predominant risk allele (Nair et 
al., 2006): individuals with this allele have a 10-20-fold increased risk of developing psoriasis 
(Mallon et al., 1999).  
HLA-Cw6 positive and negative psoriasis patients may exhibit distinctive clinical 
phenotypes (Henseler & Christophers, 1985): guttate psoriasis is mostly confined to HLA-
Cw6+ patients meanwhile psoriatic nail disease, palmoplantar pustulosis and psoriatic 
arthritis are more common in HLA-Cw6- patients (Fan et al., 2007; Gudjonsson et al., 2006). 
Furthermore, partial or total remission during pregnancy is much more frequent in HLA-
Cw*0602+ women (Gudjonsson et al., 2006).  
Despite this strong association, the functional role of HLA-Cw6 remains unknown; as far as 
we know  HLACw6 may exert its effect through the specific or the innate immune system 
(Figure 2): HLA-Cw6 may act via the adaptive immune system by its antigen presenting 
capacity and the fact that guttate psoriasis (sturdily associated with HLA-Cw6) is triggered 
by streptococcal pharyngitis (J. C. Prinz, 2001), supports this hypothesis. HLA-Cw6 may 
also exert an innate immune response via its interaction with KIRs  (killer immunoglobulin-
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like receptors) of natural killer (NK) and natural killer T (NKT) cells, which are implicated, 
in psoriasis pathogenesis (Nickoloff, 1999a). KIRs recognize different types of HLA-C 
molecules leading to either an overall activating or inhibitory immune response. KIRs have 
been associated with psoriasis and PsA (Martin et al., 2002). HLA-Cw6 is a natural ligand 
for KIR2DL1 (an inhibitory receptor) and it is possible that interaction between HLA-Cw6 
and PaKIR2DL1 would lead to aberrant function of lymphoid cells in psoriasis 
pathogenesis. 
 
Fig. 2. Hypothetical regulating role  of HLA-Cw6 in both specific and innate immune 
responses. 
HLA-Cw6 expressed on APCs can trigger specific immune responses by presentation of 
processed antigen to the TCR of CD8+ T cells. Also, innate immune response can be elicited 
by interaction of HLA-Cw6 with its natural Killer immunoglobulin-like receptors expressed 
on NK and NKT cells. 
A new psoriasis susceptibility gene ZNF313/RNF114, which may regulate T cell activation 
through ubiquitin ligase activity, has been identified (Capon et al., 2008). All these data 
further supports the concept that multiple gene products share a role in the immune 
regulation of psoriasis, contributing to disease pathogenesis.  
4. Immune response 
Although the initial event triggering a psoriatic lesion is still unknown many factors have 
been shown to play a role in the pathogenesis of psoriasis:  physical trauma, infections, 
stress, drugs, alcohol and smoking can all trigger an initial episode of psoriasis in 
individuals with genetic predisposition (Bowcock & J. G. Krueger, 2005). 
This initial trigger activates dendritic cells, favoring their migration to skin-draining lymph 
nodes, where antigen-specific T cells (primed by DCs) differentiate into effector T cells, 
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which  then traffic to the skin where they induce – in concert with other cells, especially 
dermal DCs – the creation of a primary psoriatic plaque. During this step some T cells and 
DCs start to infiltrate the epidermis, where stimulating KCs support  the typical epidermal 
changes (Bowcock & J. G. Krueger, 2005). 
Epidermal keratinocytes are able to recruit and activate T cells and most T cells infiltrating 
psoriatic skin are divided into Th1 (CD4+) and T cytotoxic 1 (Tc1; CD8+) subsets (J. G. 
Krueger, 2002). Two further T cell subtypes, Th17 cells (McKenzie et al., 2006) and 
regulatory T cells (Treg) (Sugiyama et al, 2005) have been identified as important 
contributors to the pathogenesis of autoimmune diseases such as psoriasis (Figure 3).  
 
Fig. 3. Role of CD4 T cell subtypes in psoriasis. 
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Th1 and Th17 pro-inflammatory cytokines mediate keratinocyte hyperproliferation and 
trigger a ‘vicious cycle’ of inflammation. IL-23 secreted principally by keratinocytes, 
dendritic cells and macrophages  is critical for maintenance of Th17 function. Low levels of 
anti-inflammatory cytokines released by Th2 and Tregs potentially counteract but cannot 
balance the effects of Th1/Th17 cytokines.  
From the foregoing it is clear that the contribution of both innate and adaptive immune 
responses are important in mediating the inflammatory psoriasis cascade (Gaspari, 2006) 
(Figure 1). 
4.1 Aberrant activation of the innate fraction of the skin immune system 
The present knowledge of the possible role of innate immunity cells (Kcs, Dcs, neutrophils, 
macrophages, NK and NKT cells) in psoriasis will be discussed.  
4.1.1 Keratinocytes in psoriasis 
Over the last 20 years it has been regularly discussed if psoriatic skin lesions arise from a 
primary alteration in epidermal keratinocytes or in T cells (Figure 1); the current view is that 
infiltrating T cells initiate and maintain psoriasis. In this vision, cytokines (e.g., IL-1, IL-6 
and IFN-) secreted by T cells and other inflammatory cells (DCs, macrophages and 
neutrophils) would trigger KCs hyperproliferation,   inducing epidermal hyperplasia (J. G. 
Krueger, 2002). In particular, IL-23, whose expression is increased in psoriatic lesion (Piskin 
et al., 2006), has been implied in the development of epidermal acanthosis, most likely 
through the induction of IL-22 (Zheng et al., 2007); injection of  IL-23 into mouse dermis 
induces as dermal inflammation as epidermal hyperplasia similarly to features seen in 
psoriasis (J. R. Chan et al., 2006).  
Previous studies (J. G. Krueger, 2002) suggested an additional explanation for the chronic 
epidermal hyperplasia in psoriatic lesions: the migration of T cells in the epidermis would 
firstly break the basement membrane, which has been shown to have large areas with 
reduced staining intensity for collagen IV and laminins (Fleischmajer et al., 2000), and 
secondly disrupt desmosome connection between KCs. These two events could be 
interpreted by KCs as an injury and therefore induce a wound repair response. As a 
consequence many mitogenic cytokines would be released by KCs triggering a regenerative 
epidermal growth. Hence, T cells in psoriatic epidermis would be responsible for the chronic 
hyperplasia as by releasing pro-inflammatory cytokines as by disrupting epidermal 
integrity. 
Another evidence against the fundamental role of T cells in psoriasis arise from the 
observation that HIV+ patients (which usually have reduced number of CD4+ T cells) 
develop psoriasis with similar frequency as the rest of the population (Namazi, 2004).  
Finally, in 2005 Zenz et al. reported an interesting animal model with psoriasis-like features 
(Zenz et al., 2005); They knocked out JunB and c-Jun, two components of the AP-1 
transcription factor, which control cell proliferation and differentiation , cytokine 
production, and stress responses in the skin. The importance of this animal model lies in the 
fact that JunB is located in the PSORS6 locus, which has been shown to be a psoriasis 
susceptibility region (Hensen et al., 2003). Interestingly, these mice developed not only 
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inflammatory skin lesions but also a form of destructive arthritis. This evidence suggested 
that alteration in the epidermal Jun-pathway may be sufficient to induce inflammatory 
reactions in the skin as well as in the joints. At the skin level these mice showed typical 
hallmarks of psoriasis: hyperkeratosis, enlarged blood vessels, infiltration of T cells and 
neutrophils, and up-regulation of pro-inflammatory cytokines.  
The most intriguing aspect was the examination of the T cells role in development of 
psoriasis in a genetic model: upon deletion of JunB and c-Jun proteins in Rag2-deficient mice 
(mice deficient of  T/B cells), skin changes like in psoriasis were still induced, though they 
were milder. These data suggest a minor role for T cells in the etiology of psoriasis-form 
skin inflammation, and that primary alterations in KCs were sufficient to drive psoriasis-
form changes in the mice skin. But before stating that KCs instigate psoriasis in humans, the 
relevance of this model must be discussed further. A recent study (Haider et al., 2006) 
showed that the JunBwas expression increased in psoriatic plaques instead of 
decreased/deleted as in the Zenz mouse model, suggesting a role for JunB as a 
transcriptional activator of disease-related genes in psoriatic KCs.  
The ongoing discussion about the primary instigator of psoriasis reflects the complexity of 
this disease and the still elusive interplay between KCs and immune cells in driving 
psoriasis. 
This problem was further addressed in a another mouse model, in which STAT-3 was 
constitutively activated in basal KCs under the control of the keratin 5 promoter (K5.Stat3C) 
(Sano et al., 2005). As in human psoriatic plaques, induced lesions of K5.Stat3C mice shown 
a considerable number of CD4+ T and CD8+ T cells in the epidermis. For psoriasis 
development, this model required both activated STAT-3 in KCs and activated T cells in the 
dermis and epidermis of the transgenic rodents, suggesting the theory that KCs and T cells 
could act together in psoriasis pathogenesis. 
4.1.2 Neutrophilic granulocytes 
Early studies in psoriasis (Jablonska, 1986), in which the initial (pre-pinpoint) lesions  were 
studied histologically,indicated that the primary abnormality in a developing lesion of 
psoriasis is the perivascular accumulation of neutrophils as well as their epidermis invasion 
(Kogoj  phenomenon). Next, these neutrophils accumulations lead to microscopically 
detectable microabscesses (Munro abscesses). In many patients with psoriasis, these 
micropustules may enlarge and become clinically visible as sterile 2–3-mm pustules. In some 
patients, pustules are the primary visible abnormality, often on an erythematous base. 
The presence of neutrophils must be important for the formation of psoriatic skin lesions, in 
fact agranulocytosis has been reported to result in the remission of psoriasis (Toichi et al., 
2000). Next, neutrophils can contribute to the hyperproliferation of keratinocytes by the 
effects of human leucocyte-derived elastase (Rogalski et al., 2002). 
4.1.3 Natural killer T cells  
The potential role of cells expressing NK receptors in psoriatic skin was firstly  proposed by 
Nickoloff  (Nickoloff et al., 1999b); in further experiments, he showed that a CD94+/CD161+ 
NKT cell line (isolated from a psoriatic patient) injected in prepsoriatic skin of a SCID 
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mouse, gave rise to creation of psoriatic plaque characterized by diffuse keratinocyte 
expression of CD1d, CD161+ T cells infiltration and marked presence of mRNA for IFN-c 
and IL-15 (Nickoloff et al., 2000). 
In line with these data, it seems that constitutive CD1d expression on prepsoriatic skin 
keratinocytes represents a primary prerequisite that ensures their contact with the CD161 
molecule on NKT cells. This interaction might also represent one of the critical events in the 
triggering of psoriasis as CD1d-bearing keratinocytes can present endogenous (self) or 
exogenous (bacterial, viral) glycolipids to NKT-cells. Consequently to the recognition of 
glycolipid antigens, NKT cells produce large amounts of IFN-c which induces stronger 
keratinocyte expression of CD1d; in this way the pathogenic mechanism of psoriatic plaques 
is not only initiated but also maintained. 
Numerous studies have addressed the issue of NKT cells in the lesional skin of psoriasis 
patients and a constant result evidenced by independent groups of investigators is that 
CD161+ T cells appear in greater numbers in lesional skin of patients with psoriasis than in 
normal healthy skin and/or prepsoriatic skin (Bonish  et al., 2000; Cameron et al., 2002; 
Curry et al., 2003; Vissers et al., 2004a).  
However, Curry group shown a greater frequency of CD161+ T cells yet in the prepsoriatic 
skin in comparison with the normal skin, suggesting that certain immune response 
dysregulations exists in the uninvolved skin and creates a milieu, promoting the psoriatic 
lesions onset  (Curry et al., 2003). 
A flow cytometric analysis of psoriatic tissue-infiltrating T cell demonstrated the presence of 
CD3+ cells expressing also CD16, CD56, CD158b, CD94 or NKG2A and CD4–CD8–, the 
majority of these is a subset of NKT cells (Liao et al., 2006). In addiction a recent study (Zhao 
et al., 2008) confirmed that NKT cells as well as CD1d molecules were increased within 
psoriatic skin. 
The supposed pathogenic role of NKT cells in psoriasis is also supported by the effects of 
different pharmacological treatments, that decreases NKT cell numbers in psoriatic plaques, 
in particular the clinical efficacy of  betamethasone dipropionate (Bovenschen et al., 2007; 
Vissers et al., 2004b, 2008;) and similarly of alefacept that induce an improvement in plaque 
severity accompanied by significant reductions of dermal CD94+ and CD161+ (Bovenschen 
et al., 2007). 
In general, these data strongly indicate that lesional CD94+ and CD161+ NKT cells actively 
participate in the development and/or maintenance of psoriatic lesions, but the relative 
relevance of each of these subsets remains elusive. However, it might be hypothesized that 
epidermal NKT cells play a major pathogenic role due to their direct interaction with CD1d+ 
keratinocytes and the resulting hyperproliferation while the dermal component of NKT cells 
participates in the immune response through the interaction with CD1d-bearing dermal 
dendritic cells and monocytes. 
Likewise other Th1-mediated autoimmune diseases, psoriasis is associated with decreased 
numbers of circulating NKT cells (Cameron et al., 2003; Koreck et al., 2002; van der Vliet et 
al., 2001;); Koreck reported that decreased percentage of NKT cells population in blood of 
psoriasis patients tended to be even lower in those with frequently relapsing (Koreck et al., 
2002). Moreover, different systemic therapy regimens resulted in the recovery of these cells, 
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but their percentage remained significantly lower in comparison with healthy control 
subjects. In contrast, Langewouters group showed that the number of circulating CD94+ an 
CD161+ cells was significantly higher in patients with moderate-to-severe as compared to 
patients with mild psoriasis (Langewouters et al., 2008). It has been also reported that 
circulating CD161+ NKT cells in people with severe psoriasis belong to Th1 cells (W. L. Chan 
et al., 2003) and that treatment with alefacept or efalizumab causes significant reduction in 
their number (Larsen et al., 2007; van Lingen et al., 2008). These observations imply that 
distinct subsets of NKT cells differentially regulate immune responses and that their relative 
imbalance might be of importance in the psoriasis pathogenesis, but the precise impact of 
these findings remains unclear. 
4.1.4 Accessory cells (Dendritic cells and macrophages) 
DCs are involved in the development of tolerance (Steinman et al., 2003) and are the unique 
professional antigen-presenting able to take up antigen in the tissue they reside in and to 
migrate to the draining lymph nodes; here activate naive T cells, generating specific T-cell 
responses (Teunissen, 2005).  
In the peripheral tissues DCs receive all kinds of microenvironment signals, that influence 
the their maturation process, determining the phenotype and function of mature DCs and 
their type 1 ⁄type 2 polarizing potential. In case of risk (e.g. infection, cancer), DCs will 
transform into strong stimulatory antigen presenting cells, whereas under non pathological 
steady-state conditions DCs do not reach full maturation and they will present self-peptides 
⁄MHC complexes in the presence of insufficient costimulatory molecules, inducing  T-cell 
anergy or expansion of regulatory T cells (peripheral tolerance). If this delicate balance of 
immune reactivity vs. tolerance is broken, chronic inflammatory diseases, like psoriasis, 
may develop. 
In the absence of pathogenic substances, stress signals from neighbouring cells (e.g. necrotic 
cells) can activate DCs enabling them to stimulate naive T cells (Gallucci et al., 1999). In 
relation to this, Krueger has expressed an remarkable view concerning traumatic injuries 
(breaches in the basement membrane and disruption of desmosome connections between 
adjacent keratinocytes) caused by migrating T cells and DCs in the epidermis, that are 
possibly involved in the development of psoriasis lesions (J. G. Krueger, 2002). 
Keratinocytes will respond to these defects by overproduction of cytokines, among others 
TNF-a, a key cytokine to induce DC migration/maturation.  
Another exciting point to mention is the observation that DC development is also affected 
by mutual interaction with NKT cells (Taniguchi et al., 2003): weak responses by NKT cells 
to glycolipid ⁄CD1d complexes can be enhanced by DC-derived IL-12, resulting in up-
expression  of IFN-c by NK T cells. This interaction may be relevant in psoriasis. 
DCs are numerous in the dermal part of psoriasis skin  and many of them exhibit an 
activated phenotype (CD80+, CD83+, CD86+ and DC-LAMP+) (Abrams et al., 2000; 
Teunissen, 2005) and may be an important source of TNF-a (Nickoloff et al., 1991; Zhou et 
al., 2003).  
Recent evidences from different genetic mouse models show that also the macrophages can 
contribute to T-cell-mediated and epidermis-mediated psoriasis-form skin inflammation  
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and in particular the data from the CD18hypo PL/J psoriasis mouse model demonstrate 
(Wang et al., 2009) that the psoriasis-form inflammatory skin disorder critically depends on 
an appropriate activation of macrophages, with ample release of TNF-a.  
In human psoriasis, the number of epithelium-lining macrophages was reported to increase 
in lesional skin. These macrophages can play a role in the regulation of epidermal 
proliferation and differentiation (van den Oord & de Wolf-Peeters, 1994);  also vigorous 
interactions between macrophages and keratinocytes (Djemadji-Oudjiel et al., 1996) may be 
involved in the psoriasis pathogenesis (van den Oord & de Wolf-Peeters, 1994).  
Macrophages, under different conditions, secrete various pro-inflammatory cytokines: TNF-
, IL-1b, IFN-, IL-6, IL-10, IL-12, and IL-18, (Willment et al., 2003) and notably, in a recent 
study CD68+ macrophages  were identified as important TNF-source in human psoriasis 
and upon treatment with anti-TNF- antibody macrophage levels decreased in the plaque 
psoriasis, with clinical psoriasis resolution (Marble et al., 2007). In according to this finding, 
it is also showed that CD68+ macrophages as important TNF- source in human psoriatic 
skin, which had distinctly decreased number and TNF- concentration following bath-
PUVA therapy (Wang et al., 2009). This was also found in a T-cell-independent mouse 
model, with an increase of TNF- in macrophages (Stratis et al., 2006). 
Based on literature data, an emerging model of psoriasis pathogenesis in humans suggests 
that dermal macrophages, activated by T-cell cytokines, produce large amounts of TNF-, 
leading to skin changes (Clark & Kupper, 2006). 
4.2 Dysfunction of the adaptive immune response cells 
Until the 1990s, psoriasis was thought to be a disease of disordered keratinoctye 
proliferation and differentiation (G. G. Krueger et al., 1984) and  epidermal hyperplasia was 
the most prominent clinical and histological feature. For this reason, the old psoriasis 
treatments using antimetabolites including methotrexate which limit epidermal 
hyperproliferation. However, successive evidence from clinical studies and, experimental 
models support the theory that psoriasis is a T cell-mediated inflammatory skin disease 
(Lew et al., 2004) affecting genetically predisposed individuals and the epidermal 
hyperplasia is an effect of cellular immune infiltration. 
4.2.1 Role of T cells 
The first evidence resulting in psoriasis being widely considered as a T cell mediated 
autoimmune disease came from the success in the psoriasis treatment of T cell-targeted 
therapies such as cyclosporine (Baker et al., 1987), tacrolimus (Jegasothy et al., 1992) or CD4-
specific monoclonal antibodies (Moabs) (J. Prinz et al., 1991).  
A pivotal study involved the testing of IL-2-diphtheria-toxin fusion protein in psoriasis 
patients (S. L. Gottlieb et al., 1995). This agent selectively depleting activated T cells that 
express IL-2 receptors from psoriasis skin lesions and resulted in clinical remission of 
psoriasis vulgaris.  
Subsequently, administration of another fusion protein, cytotoxic T-lymphocyte antigen 4 
(CTLA4)-antibody, was shown to reverse the clinical and cellular features of psoriasis 
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(Abrams et al., 1999). This agent blocks T cell co-stimulation mediated by DCs without 
directly deplete T cells. Its effectiveness indicated that continuing T cell co-stimulation is 
required to sustain psoriasis disease activity, including the excessive infiltration of T cells 
and DCs into the skin (Abrams et al., 2000). All these clinical results confirmed that lesion-
associated T cells are central to sustaining disease activity in psoriasis.  
Additional evidence highlighting the implication of T cells in psoriasis pathogenesis have 
been reviewed (Nestle et al., 2009) including the appearance of clonal T cells in psoriatic 
lesions (Menssen et al., 1995); the development of psoriasis-form phenotype within 
symptomless psoriatic skin after transplantion onto the xenotransplantation AGR 129 mouse 
model again underlines the importance of epidermal T cells in psoriasis genesis  (Conrad et 
al., 2007).  
Also, based on the findings that expansion of skin resident T cells is important in psoriasis 
progress in the xenotransplantation AGR mouse model, the function of tissue-specific 
factors in activation and expansion of resident T cells has been further explored (Conrad et 
al., 2007). T cells need to pass through the dermo-epidermal junction in order to go into the 
epidermis and collagen fibrils are an essential part of the dermo-epidermal junction. The 
most important basement membrane collagen is collagen IV and long-term activation of T 
cells results in the expression of a receptor for collagen IV, the heterodimeric integrin . 
It has been shown that epidermal accumulation of + Th1 and Tc1 cells correlate with 
psoriasis development. Blocking  with a neutralizing Moab prevents epidermal T cell 
accumulation and subsequent psoriasis development in the xenotransplantation AGR 
mouse model.  expression can act as a checkpoint for entry of T cells into epidermis 
with + epidermal T cells potentially playing an important role in psoriatic lesion 
formation.  
In conclusion, targeting of these integrins may offer new and effective therapeutic 
approaches in psoriasis. 
4.2.2 The IL-23/Th17 pathway  
The IL-23/Th17 pathway is an exciting area in psoriatic pathology (Figure1) because it has 
led to the development of promising innovative treatments which specifically target this 
pathway (D'Elios et al., 2010). The development, characterization and function of Th17 cells 
and the role of IL-23 in Th17-cell dependent chronic inflammation in psoriasis have been 
recently reviewed (Di Cesare et al., 2009). Briefly, IL-23 is a heterodimeric cytokine 
(Oppmann et al., 2000) composed of the subunits IL-23p19 and  IL-12p40 (an IL-12 subunit). 
Intradermal injection of IL-23 in mice resulted in the development of a psoriasis-form 
phenotype with histopathological features (Chan et al., 2006). IL-23 can mediate epidermal 
hyperplasia, acanthosis, hyperparakeratosis and orthohyperkeratosis by way of TNF-, IL-
20R2 and IL-22 (Chan et al., 2006; Zheng et al., 2007). These data are supported by findings 
in humans including an mRNA over-expression of IL-23p19 and IL-12p40 seen in psoriatic 
skin lesions, compared to uninvolved skin. Further other results indicate that IL -23 
production  occurs at inflammatory skin sites and is mediated by tissue-resident and/or 
recruited immune cells, such DCs and KCs (Piskin et al., 2006).  
The pathogenic role of IL-23 in psoriasis is strongly supported by the clinical findings that 
anti-TNF- agents can reduce IL-23p19 and IL-12p40 mRNA levels also the reduction of IL-
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23 level caused by cyclosporin A, UV therapy and biological agents correlates to clinical 
improvements in psoriasis patients (A. L. Gottlieb et al., 2005; Haider et al., 2008; Piskin et 
al., 2004). 
Transforming growth factor (TGF)-1, IL-6 and IL-21 are all required to transform naïve T 
cells into cells expressing the unique lineage-specific transcription factor, RORC variant 2 
and IL-23 receptors with subsequent binding of IL-23 resulting in differentiation into Th17 
cells. 
Th17 cells in turn produce the pro-inflammatory  cytokines IL-17A, IL-17F, IL-22 and IL-26 
(Langrish et al., 2005) that activate KCs leading to hyperproliferation and production  of  
proinflammatory cytokines / chemokines, which recruit and activate other immune cells in 
the inflamed skin, enlarging the inflammatory response and consequently the clinical 
disease features. Another support for a role of the IL-23/Th17 pathway in psoriasis comes 
from whole genome studies showing that genetic variants of the IL-23 receptor are 
associated with psoriasis (Capon et al., 2007).  
Regarding the clinical relevance of the IL-23/Th17 pathway, targeting the common subunit 
p40 of IL-12 and IL-23 demonstrated clinical improvement in psoriasis. Two anti-IL-12p40 
Moabs, ustekinumab and ABT-874, have been recently developed as psoriasis cures. As we'll 
see in more detail later, ustekinumab and ABT-874 are humanized IgG1 Moabs that binding 
to the p40 subunit of human IL-12 and IL-23, prevents interaction with IL-12Rb1. Phase I 
(Kauffman et al., 2004)  and phase II (Kimball et al., 2008b; G. G. Krueger et al., 2007)  studies  
supported the use of both antibodies as effective treatments for psoriasis.  
The safety profile of ustekinumab in psoriasis has been evaluated in 2 phase III studies. Of 
these, PHOENIX I assessed the efficacy and safety of ustekinumab 45 and 90 mg 
administered subcutaneously at weeks 0, 4, and then every 12 weeks over 76 weeks of 
treatment (Leonardi et al., 2008). 67.1 % and 66.4 % of patients who received ustekinumab 
45mg and 90 mg respectively, achieved PASI-75  at week 12 compared to placebo control 
(3.1 %). The observed adverse events were mild, non-life threatening and not significantly 
different from the placebo group. The most commonly reported adverse events were 
upper respiratory tract infections, nasopharyngitis, headache, and arthralgia. The 
PHOENIX II trial (Papp et al., 2008) was conducted to further assess if dosing 
intensification would increase the response to treatment in partial responder patients 
(between PASI-50 and PASI-75). It was found that dosing intensification resulted in 
increased clinical efficacy only in patients receiving 90mg, but not 45mg, of ustekinumab 
every 8 weeks (PASI-75 in 68.8 % of patients receiving 90mg every 8 weeks versus 33.3 % 
of patients receiving 90 mg every 12 weeks). The incidence and type of adverse events 
observed did not differ between PHOENIX I and II studies. Ustekinumab is also effective 
in the treatment of psoriatic arthritis and this study again confirmed that ustekinumab is 
well tolerated (A. Gottlieb et al., 2009). 
4.2.3 Regulatory T cells 
Regulatory T cells (Tregs) are characterized by their ability to suppress the activation and 
proliferation of  effector T cells (CD4+/CD8+)  by direct contact with antigen presenting cells 
(Gondek et al., 2005) or by releasing IL-10 (Annacker et al., 2003) and/or TGF-1 (Nakamura 
et al., 2004) (Figure 3).  
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Tregs express CD4, height CD25 and Foxp3 and are about the 1-5 % of the total population 
of peripheral CD4+ cells.  
Dysfunction of Tregs has been implicated in the pathogenesis of various autoimmune 
diseases such as multiple sclerosis and rheumatoid arthritis (RA) and in psoriasis; where 
Treg function and proliferation are both defective (Sugiyama et al., 2005). This combination 
may result in a failure to limit the activation and proliferation of pathogenic T cells, 
contributing to the ongoing inflammation seen in psoriasis; for this reason strategies that 
correct Treg function or increase the Treg/pathogenic T cell ratio may be potential 
treatments for psoriasis (Sugiyama et al., 2005). Phototherapy, for example,  might induce 
Treg type suppressor cells as well as eliminate pathogenic T cells (Baadsgaard et al., 1990), 
supporting a possible role of Treg cells in protection against psoriasis. 
5. Principal co-morbidities 
Today we know that during the time course of psoriasis, certain conditions may appear at 
somewhat unpredictable time points in a progressive fashion. These so-called co-
morbidities, often become manifest years after the onset of skin manifestations and are 
frequently observed in severe forms of psoriasis. 
5.1 Psoriatic arthritis  
PsA is traditionally included among common co-morbidities of psoriasis, even if it should 
be rather considered a component of the clinical spectrum of psoriatic disease. Skin 
manifestations occur before the onset of arthritis in the large majority of patients (A. B. 
Gottlieb et al., 2006), and in general, the prevalence of arthritis in psoriasis patients is 
estimated to be approximately 30% (Gisondi et al., 2005; Zachariae et al., 2002).  
In PsA pathogenesis the TNF- plays a key role, promoting osteoclastogenesis and bone 
resorption by stimulating the receptor-activator of NFkB, expressed in bone marrow 
osteoclast precursors (Abu-Amer et al., 2000; Keffer et al., 1991). Moreover, TNF- has been 
noted to increase DKK-1 (dickkopf-1), a glycoprotein able to inhibit the bone apposition 
process by obstructing osteoblast growth (Baron & Rawadi, 2007; Diarra et al., 2007).  
Numerous clinical observations support these experimental data, particularly a number of 
clinical trials showed a significant inhibition of joint damage in patients who underwent 
anti-TNF therapy, confirming the role of TNF in altered bone remodeling. 
Approximately 20% of PsA patients are estimated to suffer from a severe and destructive 
form of arthritis, that leads to overall increased disability (D. D. Gladman et al., 1990; 
Queiro-Silva et al., 2003). Interestingly, different results indicate that the DMARDs (disease-
modifying antirheumatic drugs) might not be able to inhibit disease progression and 
osteoarticular damage, even though they are generally useful in providing relief of clinical 
symptoms (Kana et al., 2003). 
There is also convincing evidence of increased mortality in PsA patients, which seems to be 
related to disease activity, characterized by high erythrosedimentation rate, high medication 
level, and significant radiological damage at early patient visits (D. D. Gladman et al., 1998). 
Fortunately, as we shall see later, the mortality in PsA patients has gradually improved by 
using the biological drugs (Ali et al., 2007). 
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5.2 Inflammatory bowel disease (IBD) 
IBD commonly refers to ulcerative colitis (UC) and Crohn’s disease (CD), which are 
chronic inflammatory diseases of the gastrointestinal tract with unknown etiology. UC 
and CD have significant clinical differences, however, both diseases share similar 
pathogenic mechanisms and many extra-intestinal manifestations, and frequently respond 
to the same treatments. 
Many data indicate a stringent correlation between CD and psoriasis (Najarian & A. B. 
Gottlieb, 2003). Firstly, CD patients have been found to have a seven-fold higher risk of 
developing psoriasis than control subjects (Mrowietz et al., 2006). This association may be 
related to the following observations: a) it has been shown that TNF- has a key role in both 
conditions, valuing the hypothesis of common inflammatory pathways. This point has been 
further supported by the therapeutic efficacy of anti-TNF- antibodies; b) genetic evidences, 
such as polymorphisms in the TNF- promoter region and the close position of the 
susceptibility loci, link psoriasis to CD (Najarian & A. B. Gottlieb, 2003). In particular, a 
recent study demonstrated a significant association between CD and the IL-23 receptor gene 
(Duerr et al., 2006) and, as reported previously,  IL-23 /IL-17 pathway is involved in 
psoriasis pathogenesis (Blauvelt, 2008; Rizzo et al., 2011). 
On the other hand, the association between psoriasis and UC has been described in only in 
recent studies, even if the first studies regarding this connection trace back to the 60s and 
early 70s (Brewerton et al., 1974; McEwen et al., 1971). Most recently, Cohen et coll. (Cohen 
et al., 2009), in a case-control study with 12,502 psoriasis patients, demonstrated that even 
though not as high as CD (odds ratio 2.49), UC association is statistically significant and far 
from being negligible (odds ratio 1.64). This often undervalued correlation is biologically 
conceivable because chronic systemic inflammation and TNF- constitute core features of 
UC, as well as psoriasis (Torres & Rios 2008). 
5.3 Metabolic Syndrome (MS) and Cardiovascular Diseases (CVD) 
Different overlapping guidelines have been proposed to define the MS: the cardiometabolic 
risk factors of obesity, impaired glucose tolerance (or type 2 diabetes), insulin resistance, 
dyslipidemia, and hypertension (Alberti et al., 2006; Grundy et al., 2005; Johnson & 
Weinstock, 2006). Just like psoriasis, MS is characterized by a pro-inflammatory state, 
characterized by a complex cytokines network. 
In response to various metabolic signals the adipose tissue release the adipokines that 
modulate flogosis, lipid metabolism, and insulin sensitivity. A cluster of these adipokines is 
represented by pro-inflammatory cytokines (TNF-, IL-8 and IL-6) whose overproduction 
drives the psoriasis pathogenesis, as well as of certain basic features of MS like insulin 
resistance and diabetes (Arican et al., 2005; Nickoloff & Nestle, 2004; Rondinone, 2006). 
Consistent with this common pathophysiology, different studies have demonstrated that 
psoriasis patients show an increased risk of developing the metabolic syndrome (Henseler & 
Christophers, 1995; Neimann et al., 2006). 
The multiple conditions that constitute the MS could very well be the main reasons for CVD 
in psoriasis patients. 
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However, in various studies involving patients with psoriasis, the latter was identified as an 
independent risk factor for myocardial infarction regardless of the presence of the complete 
MS and an independent risk factor for coronary artery calcification (Gelfand et al., 2006).  
Indeed, as of today there is forceful evidence that psoriasis, much like other systemic pro-
inflammatory conditions (e.g. RA, SLE), may predispose to an increased CVD risk, 
following a nontraditional pathway to atherogenesis and premature vascular damage 
(Kimball et al., 2008c; Saphiro et al., 2007).  
In conclusion, basic inflammatory activity in psoriasis could act independently of traditional 
risk factors, MetS included, and can increase the risk of CVD through its own underlying 
biological mechanisms (inflammation-driven atherogenesis). 
 
Cell Types Biological Effects Clinical Consequences 
Leukocytes Activation/maturation 
↑ inflammatory 
cytokine/expression 
ROS release 
↑ Inflammation  
Endothelial injury 
Epidermal Proliferation 
Endothelial cells  Suppression of precursor 
cells/apoptosis 
↑ expression of adhesion 
molecules 
↑ release of VEGF 
Impaired NO Bioavailability 
Induction of TF expression 
↑ Angiogenesis 
↑ leukocytes recruitment 
Endothelian dysfunction 
Hemostasis impairment  
Osteoclast precursors ↑ RANKL expression 
(↑osteoclast 
maturation/activation) 
↑ DKK-1 level (↓ osteoclast 
development) 
Bone resorption promotion 
Bone apposition inhibition 
Condrocytes/Synoviocytes Apoptosis 
↑ Metalloproteinase synthesis
Articular erosion 
Adipocytes Dysregulation of lipid and 
glucose metabolism 
↑ circulating levels of FFA 
and LDL 
Disadvantageous metabolic 
response to injury and 
infection 
↑ in traditional CV risk 
factors 
Hepatocytes Induction of IL-6 Raised CRP serum levels 
CRP-induced vascular 
dysfunction  
Neural cells Modulation of cell 
proliferation  NGF-induced  
Neurogenic inflammation 
↑ = Increase;  ↓ = decrease; CRP = C-reactive protein; CV = Cardiovascular; DKK-1 = Dickkopf-1; LDL = 
Low-density lipoproteins; NGF = Nerve growth factor; NO = Nitric oxide; RANKL = Receptor-
Activator of NFkappaB ligand; ROS = Reactive oxygen species; TF = Tissue Factor; VEGF = Vascular 
endothelial growth factor. 
Table 1. Biological effects and clinical consequences of  TNF- stimulation in different cells     
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Recently, some studies have also shown that in psoriasis patients, the increased risk for 
myocardial infarction varies by age (higher in younger individuals) and disease severity 
(higher in severe forms) (Gelfand et al., 2006; Kremers et al., 2007; Mallbris et al., 2004). As 
such, a young patient with severe psoriasis is burdened by a CVD risk comparable with 
what is seen in the presence of traditional risk factors such as diabetes and hypertension. 
Moreover, a variety of data indicates that psoriasis and CVD (mostly atherosclerosis) share 
common pathogenic features: both Th1 mediated, with an up-regulation of Th1 cytokines 
(TNF-, IFN-) and a systemic expression of adhesion molecules, neoangiogenesis factors, 
and superantigens, these latter potentially able to activate the T cells (Biedermann et al., 
2004; Ettehadi et al., 2004; Gudjonsson et al., 2004). The table 1 summarizes the 
consequences of the TNF- over-expression in promoting inflammatory conditions such as 
psoriasis and atherogenesis.  
Overlapping of genetic susceptibility loci between psoriasis and atherosclerosis is also worth 
mentioning, even though its role has yet to be fully understood (Becker et al., 1998).  
Lastly, the two conditions also show similar histological aspects, mainly involving T cells, 
macrophages, mast cells  and connective tissue matrix. (Nickoloff et al., 2007a;  Nickoloff et 
al., 2007b).  
Alongside the similar pathogenesis, other indirect factors might be responsible for psoriasis-
CVD association; in fact some authors have found that a number of conventional systemic 
psoriasis treatments  (e.g. methotrexate, acitretin, cyclosporine) might increase the effects of 
specific CVD risk factors (Katz et al., 1994; Strober & Menon, 2005; Taler et al., 1999). 
6. Disease evaluation 
To assess the severity of psoriasis and PsA (baseline/in response to treatment), a number of 
tools are now available, of which the Psoriasis Activity and Severity Index (PASI) is the most 
frequently used (Fredriksson & Pettersson, 1978). The PASI combines assessments of the 
extent of body surface involvement in four anatomical regions (head, trunk, arms and legs) 
and the severity of desquamation, erythema and plaque induration (thickness) in each 
region, yielding an overall score of 0 (no psoriasis) to 72 (severe psoriasis) (Fredriksson & 
Pettersson, 1978). PASI 75 is defined as a 75% reduction in PASI compared with baseline, 
instead a PASI score of >10 is defined as moderate to severe disease, necessitating systemic 
therapy (PUVA, UVB 311, MTX, cyclosporin A or biological drugs) (Pathirana et al., 2009)  
An additional tool to assess the psoriasis severity is the physician’s global assessment 
(PGA). The PGA takes into account the involvement of the body surface area, induration, 
scaling and erythema and grades the patient’s psoriasis overall, relative to baseline, as 1 
(clear), 2 (excellent), 3 (good), 4 (fair), 5 (poor) or 6 (worse) (Pathirana et al., 2009).  
In trials investigating patients with PsA, the American College of Rheumatology Criteria 
(ACR) are most commonly used. The ACR clinical response criteria are defined as 
percentage reduction [20% (ACR 20), 50% (ACR50) and 70% (ACR 70)] in tender and 
swollen joint counts and in 3 of the, remaining, 5 ACR core items (patient and physician 
global assessments, pain, disability and an acute phase reactant) (Montecucco, 2006; Radtke 
et al., 2009).  
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A supplementary tool to evaluate clinical remission in psoriatic patients is the Disease 
Activity Score (DAS) comprising the number of swollen and tender joints, the erythrocyte 
sedimentation rate and the general health of the patient (measured on a visual analogue 
scale) (Montecucco, 2006). The DAS measures 44 swollen joints, whereas the modified DAS 
28 measures only 28 swollen and tender joints (Prevoo et al., 1995). The effect of psoriasis on 
the patient’s quality of life is measured by the 10-item Dermatology Life Quality Index 
(DLQI) questionnaire. DLQI scores range from 0 (not at all) to 30 (very much) (Pathirana et 
al., 2009). 
7. Biological drugs 
Biological therapies for the treatment of psoriasis are defined by their mode of action and 
are classified into 3 groups, the inhibitors of TNF- (adalimumab, certolizumab, etanercept, 
golimumab, and infliximab), the T-cell modulating agents (such as alefacept) and the 
inhibitors of IL-12 and IL-23 (ustekinumab and briakinumab). 
7.1 TNF- inhibitors 
The TNF- inhibitors adalimumab, etanercept and infliximab have been approved by the 
FDA and EMEA for psoriasis and PsA treatment; they have been reviewed quite extensively 
in the past and the table 2 summarizes the clinical outcome for primary endpoints (e.g. PASI 
and ACR) in randomized controlled studies.  
In this chapter, instead will focus on the new TNF- blockers such as golimumab and 
certolizumab (Mössner et al., 2008; Pathirana et al., 2009).  
 
Drug Disease Trial Type Treatment
(n° of patients)
Major 
Results 
References 
Adalimumab Psoriasis 12-week 
RDBPC 
OLE until 
week 60 
A 40 mg weekly 
(50) 
A 40 mg eow 
(46) 
Placebo (52) 
PASI 75 at 
week 12: 80 
PASI 75 at 
week 12: 53 
PASI 75 at 
week 12: 4 
Gordon et 
al.,2006 
J Am Acad 
Dermatol 55: 
598–606. 
Adalimumab  
(REVEAL) 
Psoriasis 16-week 
RDBPC 
OLE until 
week 52 
A 40 mg eow 
(814) 
Placebo (398) 
PASI 75 at 
week 16: 71 
PASI 75 at 
week 16: 7 
Menter et al., 
2008 
J Am Acad 
Dermatol 58: 
106–115. 
Adalimumab 
(CHAMPION) 
Psoriasis 16-week 
RDBPC 
A 40 mg eow 
(108) 
MTX (110) 
Placebo (53) 
PASI 75 at 
week 16: 80 
PASI 75 at 
week 16: 36 
PASI 75 at 
week 16: 19 
Saurat et al., 
2008 
Br J Dermatol 
158:  
558–566. 
Adalimumab  
(ADEPT) 
Psoriasis 
arthritis   
24-week 
RDBPC 
OLE 
A 40 mg eow 
(151) 
Placebo (162) 
ACR 20 at 
week 12: 58 
ACR 20 at 
Mease et al., 
2005 
Arthritis Rheum 
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OLE week 
48 
OLE week 
104 
OLE A (281) week 12: 14
ACR 20 at 
week 48: 58.7
ACR 20 at 
week 104: 
57.3 
52: 
 3279–3289. 
Gladman et al., 
2007 
Arthris Rheum 
56:  
476–488. 
Mease et al., 
2009 
Ann Rheum Dis 
68:  
702–709. 
Adalimumab Psoriasis 
arthritis   
12-week 
RDBPC 
OLE until 
week 24 
A 40 mg eow 
(51) 
Placebo (49) 
ACR 20 at 
week 12: 39 
ACR 20 at 
week 12: 16 
Genovese et al., 
2007 
J Rheumatol 34: 
1040–1050. 
Etanercept Psoriasis 12-week 
RDBPC 
E 25 mg twice 
weekly (57) 
Placebo (55) 
PASI 75 at 
week 12: 30 
PASI 75 at 
week 12: 2 
Gottlieb et al., 
2003 
Arch Dermatol 
139:  
1563–1570. 
Etanercept 
 CONSORT 
Psoriasis RDBPC E 25 mg twice 
weekly (196) 
E 50 mg twice 
weekly (194) 
Placebo (193) 
PASI 75 at 
week 12: 34 
PASI 75 at 
week 12: 49 
PASI 75 at 
week 12: 3 
Papp et al., 
2005 
Br J Dermatol 
152:  
1304–1312. 
Etanercept Psoriasis RDBPC E 25 mg weekly 
(160) 
E 25 mg twice 
weekly (162) 
E 50 mg twice 
weekly (164) 
Placebo (166) 
PASI 75 at 
week 12: 14 
PASI 75 at 
week 12: 34 
PASI 75 at 
week 12: 49 
PASI 75 at 
week 12: 4 
Leonardi et al., 
2003 
N Engl J Med 
349: 
 2014–2022. 
Etanercept Psoriasis 12-week 
RDBPC 
E 50 mg twice 
weekly (311) 
Placebo (307) 
PASI 75 at 
week 12: 47 
PASI 75 at 
week 12: 5 
Tyring et al., 
2006 
Lancet 367: 29–
35. 
Etanercept Psoriasis 
arthritis   
12-week 
RDBPC 
E 25 mg twice 
weekly (30) 
Placebo (30) 
ACR 20 at 
week 12: 73 
ACR 20 at 
week 12: 13 
Mease et al., 
2000 
Lancet 356: 
385–390. 
Etanercept Psoriasis 
arthritis   
24-week 
RDBPC 
OLE until 
week 48 
E 25 mg twice 
weekly (101) 
Placebo (104) 
ACR 20 at 
week 12: 59 
ACR 20 at 
week 12: 15 
Mease et al., 
2004 
Arthritis Rheum 
50:  
2264–2272. 
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Infliximab  
SPIRIT 
Psoriasis RDBPC I 3 mg·kg-1 (99)
I 5 mg·kg-1 (99)
Placebo (51) 
PASI 75 at 
week 10: 72 
PASI 75 at 
week 10: 88 
PASI 75 at 
week 10: 6 
Gottlieb et al., 
2004 
J Am Acad 
Dermatol 51: 
534–542. 
Infliximab  
EXPRESS I 
Psoriasis RDBPC I 5 mg·kg-1 
(301) 
Placebo (77) 
PASI 75 at 
week 10: 80 
PASI 75 at 
week 10: 3 
Reich et al., 
2005 
Lancet 
366: 1367–1374. 
Infliximab Psoriasis RDBPC I 5 mg·kg-1 (11)
I 10 mg·kg-1 
(11) 
Placebo (11) 
PASI 75 at 
week 10: 82 
PASI 75 at 
week 10: 73 
PASI 75 at 
week 10: 18 
Chaudhari et 
al., 2001 
Lancet 357: 
1842–1847. 
Infliximab 
 EXPRESS II 
Psoriasis RDBPC I 3 mg·kg-1 
(311) 
I 5 mg·kg-1 
(314) 
Placebo (208) 
PASI 75 at 
week 10: 70 
PASI 75 at 
week 10: 76 
PASI 75 at 
week 10: 2 
Menter et al., 
2007 
J Am Acad 
Dermatol 56: 
31.e1–31.e5. 
Infliximab  
IMPACT 
Psoriasis 
arthritis   
16-week 
RDBPC 
OLE week 
50 
I 5 mg·kg-1 (52)
Placebo (52) 
ACR 20 at 
week 16: 65 
ACR 20 at 
week 16: 10 
Antoni et al., 
2005 
Arthritis Rheum 
52:  
1227–1236. 
Infliximab  
IMPACT II 
Psoriasis 
arthritis   
24-week 
RDBPC 
OLE 52 
weeks 
I 5 mg·kg-1 
(100) 
Placebo (100) 
ACR 20 at 
week 24: 54 
ACR 20 at 
week 24: 16 
Kavanaugh et 
al., 2007 
Ann Rheum Dis 
66:  
498–505. 
Golimumab  
GO-REVEAL 
Psoriasis  24-week 
RDBPC 
G 50 mg q4 wks 
(146) 
G 100 mg q4 
wks (146) 
Placebo (113) 
PASI 75 at 
week 14: 40 
PASI 75 at 
week 14: 58 
PASI 75 at 
week 14: 3 
Kavanaugh et 
al., 2009° 
Arthritis Rheum 
60:  
976–986. 
Golimumab 
 GO-REVEAL 
Psoriasis 
arthritis   
24-week 
RDBPC 
G 50 mg q4wks 
(146) 
G 100 mg q4wks 
(146) 
Placebo (113) 
ACR 20 at 
week 14: 51 
ACR 20 at 
week 14: 45 
ACR 20 at 
week 14: 9 
Kavanaugh et 
al., 2009° 
Arthritis Rheum 
60:  
976–986. 
A= Adalimumab; E = Etanercept;  I = Infliximab; G = Golimumab; OLE = Open Level Extension; q4 wks 
= every 4 weeks; RDBPC = Randomized Double-Blind Placebo Controlled Trial 
Table 2. Efficacy of anti-TNF- in the treatment of psoriasis and psoriasis arthritis   
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Up to now, treatment with  MoaB anti-TNF-has proven to be effective and relatively safe 
in patients with  psoriasis and PsA (Lima et al., 2009).  
Since TNF- has showed an osteoclast stimulating effect, alongside being synergic with 
DKK-1 in reducing osteoblasts maturation, anti-TNF- drugs should improve PsA-related 
bone altering processes, as confirmed by significant inhibition of radiographic progression 
during treatment with etanercept or infliximab (Antoni et al., 2008; Mease et al., 2006b; van 
der Heijde et al., 2007).  
Equally importantly, anti-TNF- therapy might have a preventive effect on PsA overlapping 
in psoriasis patients. In fact, in a case-control study, Gisondi group (Gisondi et al., 2008) has 
demonstrated that lower limb enthesopathy can be documented in asymptomatic psoriasis 
patients without any clinical sign of arthropathy. Similar findings were reported in the past 
concerning entheseal abnormalities (De Filippis et al., 2005) and increased Achilles tendon 
thickness (Ozcakar et al., 2005); all of which were detected in asymptomatic patients. 
Different evidences have proved that anti-TNF- treatments infliximab and adalimumab are 
effective in controlling gut inflammation, whereas etanercept is not (Bosani et al., 2009).  
There are reports of CD development in patients with ankylosing spondylitis or PsA (Song 
et al., 2008) and treated with etanercept. However, it is well-known that such patients are 
burdened with a high risk of chronic IBD development. It is therefore hard to assess 
whether these cases of CD were really a consequence of anti-TNF- therapy or rather a 
coincidental event in predisposed patients.  
The reason for the discordant effect of anti-TNF- treatments on IBD probably lies in 
different pharmacodynamic features of these drugs, and a number of hypotheses have been  
expressed in this regard.  
Firstly, it has been noted that etanercept, unlike anti-TNF- Moabs, doesn’t induce 
apoptosis of activated lymphocytes in CD patients (Van den Brande et al., 2003). Given the 
existing results, it is reasonable to conclude that etanercept has no potential to control or to 
prevent gut inflammation and hence IBD appearance. A preventive role of anti-TNF- 
Moabs against the IBD development in susceptible psoriasis patients cannot be rule out 
considering the effectiveness of these drugs in both conditions. 
About the effects of anti-TNF-a Moabs in MS and CVD, studies regarding the consequence 
on blood lipids have shown  unclear results. A study of RA patients reported a significant 
decreased atherogenic index of low-density lipoprotein (LDL)/high-densitiy lipoprotein 
(HDL) ratio after 6 months of therapy with anti-TNF-a (Spanakis et al., 2006); another 
showed increased HDL levels and reduced C-reactive protein (CRP) and IL-6 levels after 2 
weeks (Popa et al., 2005). In contrast, in some cases anti-TNF-a therapy has resulted in a pro-
atherogenic effect in RA and PsA patients, with increase of LDL/ HDL ratio and 
triglycerides levels (Dahlqvist et al., 2004). Another study demonstrated a sudden reduction 
in HDL levels the day after infliximab infusion, but without any significant variation in the 
HDL profile (Irace et al., 2004).  
No conclusions can be drawn from these inconsistent findings regarding long-term clinical 
outcomes. As a consequence, many authors seem to agree on the fact that despite the 
prominent role of TNF- on lipid regulation, the emerging efficacy of anti-TNF- therapy  
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Anti-TNF-a 
therapy 
Frequent side 
effects 
Rare severe side effects Reference 
Adalimumab  Upper respiratory 
tract infections  
 Injection site 
reactions 
 Headache 
 Severe/ Opportunistic 
infections 
 Reactivation/progression  of  
TBC 
 Onset/exacerbation of CNS 
demyelinating disorders  
(e.g. Multiple Sclerosis) 
 Increased risk of cancer  
(e.g. Lymphoma) 
 Drug-induced lupus 
 Exacerbation of congestive 
 heart failure 
 Vasculitis 
Pathirana et al., 2009 
J Eur Acad Dermatol 
Venerol 23 (Suppl. 2): 
S5–70. 
 
Smith et al., 2009 
Br J Dermatol 
161: 987–1019. 
Etanercept  Upper respiratory 
tract infections  
 Injection site 
reactions 
 Pruritus 
 Severe/ Opportunistic 
infections 
 Reactivation/progression  of  
TBC 
 Onset/exacerbation of CNS 
demyelinating disorders  
(e.g. Multiple Sclerosis) 
 Increased risk of cancer  
(e.g. Lymphoma) 
 Drug-induced lupus 
 Exacerbation of congestive 
heart failure 
 Vasculitis 
 Aplastic anaemia 
Pathirana et al., 2009  
J Eur Acad Dermatol 
Venerol 23 (Suppl. 2): 
S5–70. 
 
Smith et al., 2009 
Br J Dermatol 
161: 987–1019. 
Infliximab  Upper respiratory 
tract infections  
 Acute infusion 
reaction: 
 fever, chills, 
nausea 
 Headache 
 Pruritus 
 Urticaria 
 Elevated 
transaminases 
 Severe/ Opportunistic 
infections 
 Reactivation/progression  of  
TBC 
 Onset/exacerbation of CNS 
demyelinating disorders  
(e.g. Multiple Sclerosis) 
 Increased risk of cancer  
(e.g. Lymphoma) 
 Drug-induced lupus 
 Exacerbation of congestive 
heart failure 
 Vasculitis 
 Pancytopenia 
Pathirana et al., 2009  
J Eur Acad Dermatol 
Venerol 23 (Suppl. 2): 
S5–70. 
 
Smith et al., 2009 
Br J Dermatol 
161: 987–1019. 
Table 3. Overview of side effects of  most prescribed anti-TNF-a treatments in patients with 
psoriasis 
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on CV morbidity and mortality is likely independent of the induced blood lipid variations 
(Soubrier et al., 2008). 
Results derived from studies about the effects of anti-TNF- drugs on insulin resistance in 
psoriasis patients, appear to show an improvement in insulin sensitivity (Marra  et al., 2007). 
This outcome seems to confirm the beneficial effects of anti-TNF- Moabs already 
documented in many RA studies (Huvers et al., 2007; Yazdani-Biuki et al., 2004). In 
particular, infliximab has proved capable of enhancing insulin sensitivity after the infusion 
to up to one year (Huvers et al., 2007). Lastly, there have been few isolated cases of psoriasis 
patients with diabetes developing unpredictable hypo- or hyperglycemia after commencing 
treatment with TNF inhibitors (Boulton & Bourne, 2007; Wu & Tsai 2008).  
In the table 3 are reported the side effects of  adalimumab, etanercept and infliximab 
treatment in psoriasis patients. 
7.1.1 Golimumab (CNTO148) 
Golimumab is a human immunoglobulin G1K Moab binding both soluble and 
transmembrane forms of TNF-, thereby neutralizing their bioactivity by blocking the 
interaction with receptor (Kavanaugh et al., 2009; Xu et al., 2009). 
In a study with 337 patients, the pharmacokinetics of subcutaneously administered 
golimumab (50 or 100 mg every 4 weeks) were analyzed (Xu et al., 2009) and the following 
golimumab pharmacokinetic parameters were found: apparent clearance = 1.38 ± 0.04 L per 
day, apparent volume of distribution = 24.9 ± 1.04 L and absorption rate constant = 0.908 ± 
0.121 per day. Significant covariants on apparent clearance were identified as body weight, 
baseline C-reactive protein level and smoking habits. However, only body weight was 
found to be a significant covariant on apparent volume of distribution. In addition, 
golimumab concentrations in patients (50 mg golimumab every 4 weeks) not receiving MTX 
were 30% lower as compared with patients receiving MTX (Xu et al., 2009). So far, no 
possible explanation for the different effects of MTX on the serum golimumab 
concentrations has been provided (Xu et al., 2009). 
A randomized, double-blind, placebo-controlled phase III multicenter study was conducted 
to evaluate the safety and efficacy of golimumab from week 0 to 20 in 405 patients with 
active PsA (Kavanaugh et al., 2009).  
Active PsA was defined as at least three swollen joints and three tender joints as well as 
active plaque psoriasis with a qualifying lesion of at least 2 cm in diameter. Concomitant 
MTX, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids were permitted 
at stable doses. 
A significant reduction in PASI 75 among patients receiving golimumab 50 or 100 mg at 
week 14 (40 and 58%) was observed when compared with patients receiving placebo (3%). 
PASI 75 scores in patients with golimumab (50 and 100 mg) further improved at week 24 in 
both golimumab groups (56 and 66%), whereas only 1% of patients in the placebo group 
reached a PASI 75 (Kavanaugh et al., 2009). 
Golimumab significantly (P < 0.001) improved signs and symptoms of PsA compared with 
patients treated with placebo (Kavanaugh et al., 2009). An ACR 20 response at week 14 
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could be achieved in 51% of patients treated with golimumab 50 mg and in 45% of patients 
receiving golimumab 100 mg versus only 9% in the placebo group. At week 24, an ACR 20 
response was observed in 52% in the golimumab 50-mg group and in 61% in the golimumab 
100-mg group versus 12% in the placebo group (P < 0.001). ACR 50 and 70 responses were 
also significantly higher in both golimumab groups than in the placebo group. At week 104, 
91.4% of patients in the 50-mg group and 73.1% in the 100-mg group achieved an ACR 20 
(Kavanaugh et al., 2009). A good or moderate DAS 28 response was significantly (P < 0.001) 
more often achieved in the golimumab 50 and 100-mg recipients than in the placebo group 
at week 14 (66 and 67% vs. 24%) and at week 24 (64 and 78% vs. 24%) (Kavanaugh et al., 
2009). Assessment of physical function and health-related quality of life were measured by 
the Health Assessment Questionnaire (HAQ) and Short Form 36 Health Survey (SF-36) and 
significantly improved in both golimumab groups compared with the placebo group (P < 
0.001 for HAQ and SF-36 at all comparisons at week 24).Thus, in this study golimumab 
improved significantly the clinical signs and symptoms of PsA as well as the physical 
function and quality of life (Kavanaugh et al., 2009). 
About the of safety of this treatment, Kavanaugh and coll. (Kavanaugh et al., 2009) reported 
that 8.6% of patients treated with golimumab shown a serious adverse event up to week 104: 
serious infectious adverse events comprised sepsis/cholecystitis and abscess formation. 
about the cancers registered: one basal cell carcinoma, one colon cancer and one small lung 
cell carcinoma in the golimumab 50-mg group. In the golimumab 100-mg group, three basal 
cell carcinomas, one prostate cancer and one small lung cancer occurred.  
As for adverse events, infections of the upper respiratory tract and nasopharyngitis were 
most frequently reported. 
7.1.2 Certolizumab pegol (CDP870) 
Certolizumab pegol, a pegylated Fab-9 fragment of a humanized anti-TNF-a Moab, has been 
approved for the treatment of patients with CD (Bourne et al., 2008) and it has also been 
investigated in RA patients (Barnes & Moots, 2007). 
It binding to TNF-, blocks the interaction with specific receptors. Whereas adalimumab, 
etanercept and infliximab contain an IgG1 Fc region, which can induce antibody-dependent 
cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), 
certolizumab lacking this Fc region, isn’t able of inducing ADCC and CDC (European 
Medicines Agency [EMEA], 2008). 
Pharmacokinetic analysis in the CDP870 trial showed a bioavailability of 85% (EMEA, 2008). 
Peak plasma concentrations were attained between 54 and 171 h after subcutaneous 
injection. The mean serum concentration (Cmax) after the subcutaneous administration of 
400-mg certolizumab ranged from 46.3 ± 13.1 to 49.5 ± 8.2 mg· mL-1. An increase of Cmax 
and area under the curve (AUC) was observed with higher doses in a dose-proportional 
manner. The half-life of certolizumab was found to be approximately 14 days (EMEA, 2008)  
Certolizumab pegol has been investigated in patients with moderate to severe psoriasis. In a 
phase II trial, patients were randomized to receive certolizumab pegol 200 mg, 400 mg or 
placebo subcutaneously every 2 weeks up to week 12. At week 12, significantly more 
patients receiving certolizumab pegol 200 or 400 mg achieved PASI 75 than in the placebo 
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group (74.6 and 82.8% vs. 6.8%) (Ortonne et al., 2007). The most frequently reported adverse 
events comprised headache, nasopharyngitis and pruritus. The frequency of adverse events 
was similar across all three groups. However, serious adverse events were more common in 
the 400-mg group (7.0%) than in the 200-mg group (3.3%) and in the placebo-group (1.7%) 
(Ortonne et al., 2007). According to the data from the phase II study, PASI 75 results and 
side effects were comparable with those observed in patients treated with the approved 
TNF- blockers adalimumab and infliximab. So far, no phase III studies or studies in 
patients with PsA have been conducted. 
7.2 T-cell modulators 
In 2003, alefacept and efalizumab were the first biological agents to be approved by the 
Food and Drug Administration (FDA) for the treatment of psoriasis (Pathirana et al., 2009). 
In the European Union, only efalizumab was approved for the psoriasis therapy (Pathirana 
et al., 2009). In 2009, efalizumab was withdrawn from the market in Europe and the United 
States (EMEA, 2009; Food and Drug Administration [FDA], 2009). 
7.2.1 Alefacept 
Alefacept, a recombinant dimeric fusion protein, is made up of the terminal portion of 
leukocyte function antigen-3 (LFA-3). It binds to extracellular human CD2 and the Fc 
portion of human immunoglobulin IgG1 (Sugiyama et al., 2008). Alefacept blocks signalling 
between LFA-3 on antigen presenting cells and the CD2 molecule on T cells (primarily 
CD45RO+). 
Subsequently, the activation and proliferation of CD45RO+ T cells, which account for 
approximately 75% of T lymphocytes in psoriatic lesions, are inhibited. Furthermore, 
alefacept decreases the number of pathogenic T cells by binding CD2 on CD45RO+ T cells to 
the FcgIII receptor on natural killer cells, resulting in granzyme-mediated apoptosis of T 
cells (Gordon et al., 2003; Sobell et al., 2009; Sugiyama et al., 2008). Using a dosage of 15 mg 
alefacept administered intramuscularly QW, PASI 75 scores at week 12 were found to range 
between 21 and 35% (Gordon et al., 2003; Pathirana et al., 2009; Sugiyama et al., 2008). 
Recently, patients receiving alefacept in combination with MTX were shown to improve 
significantly in ACR 20 at week 24 compared with patients treated with MTX and placebo 
alone (54% vs. 23%; P < 0.001) (Mease et al., 2006a). 
7.3 IL-12/IL-23 antagonists 
Briakinumab and ustekinumab are both IL-12/IL-23 antagonists. Whereas briakinumab is 
currently under investigation for the psoriasis treatment in several phase III studies, 
ustekinumab was recently approved by the EMEA for the therapy of chronic plaque 
psoriasis. 
7.3.1 Briakinumab (ABT874) 
Briakinumab is a recombinant fully human, IgG1 Moab targeting the shared p40 subunit of 
IL-12 and IL-23 (Kimball et al., 2008b). It binds to soluble forms of IL-12 and IL-23, leading to 
a decreased secretion of pro-inflammatory cytokines: IL-12, IL-6, IFN- and TNF-, as 
shown in CD patients (Ding et al., 2008).  
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In a phase I trial with 64 healthy controls, the pharmacokinetics of briakinumab (0.1–5.0 
mg·kg-1 subcutaneously or intravenously) were evaluated. A linear relationship between the 
Cmax and AUC (concentration-time) was found with increasing doses. The terminal phase 
half-life time was about 9 days. No dose dependency was found for the volume distribution 
at steady state and the clearance of the drug. Subcutaneous and intramuscular application 
achieved an absolute bioavailability of 42 and 63% respectively (Ding et al., 2008). 
A phase II study with briakinumab was conducted (Kimball et al., 2008b) in patients with 
psoriasis. Patients were randomized in groups of  30 to receive either only one dose of 
briakinumab 200 mg at week 0, 100 mg briakinumab every other week for 12 weeks, 200 mg 
weekly for 4 weeks, 200 mg every other week for 12 weeks and 200 mg every week for 12 
weeks, or placebo respectively(Kimball et al., 2008b).  
PASI 75 was significantly (P < 0.001) more often reached in patients in all five briakinumab 
treatment groups (63, 93, 90, 93, and 90% respectively) compared with the placebo group 
(3%). Statistically significant improvement to briakinumab therapy was rapid and could be 
registered in the briakinumab groups as early as at week 1. During the 12-week period, 
improvement could be sustained in briakinumab-treated patients even for patients in the 
briakinumab 200 mg x 1 and 200 mg x 4 dosage groups. 
Besides injection site reactions, other common side effects the trial study comprised 
nasopharyngitis and upper respiratory infections. In addition, non-infectious serious 
adverse events reported in this study included costal chondritis in one patient. Significantly 
more patients in the briakinumab groups (36%) experienced adverse events compared with 
the placebo group (10%) (Kimball et al., 2008b). 
7.3.2 Ustekinumab (CNTO1275) 
Ustekinumab is a human monoclonal antibody binding with high affinity to the p40 subunit 
of IL 12 and IL 23 and therefore inhibiting the binding to specific receptor (IL-12Rb1) 
expressed on various cells.  
In a phase I study, patients with constant 70% PASI improvement at weeks 8, 12 and 16 shown 
significant decreases in mRNA expression of different cytokines (IL-8, IL-18 and IFN-) as 
early as week 1 (P < 0.05), whereas, in patients without PASI improvement, no significant 
reduction of cytokine mRNA expression was observed(Wittig, 2007). 
The pharmacokinetics of ustekinumab were assessed in different studies (A. B. Gottlieb et 
al., 2007; Kaufmann et al., 2004; Wittig, 2007): after a single subcutaneous injection, 
ustekinumab was slowly absorbed into the systemic circulation (mean Tmax about 12 days) 
and was afterwards slowly eliminated from the circulation (mean t1/2 around 20 days) (A. 
B. Gottlieb et al., 2007; Wittig, 2007). 
The terminal half-life (t1/2) was dose dependent and was found to range from 14.9 ± 4.6 
days (0.27 mg·kg-1 dose group) to 28.6 ± 9.3 days (2.7 mg·kg-1 dose group) (A. B. Gottlieb et 
al., 2007). Similar results were also observed for t1/2 by Kaufman (Kaufmann et al., 2004), 
ranging from 18.5 ± 3.6 in the 0.3-mg group to 25.9 ± 3.7 in the 1.0-mg group. An increase of 
Cmax and AUC was observed with superior dosages (A. B. Gottlieb et al., 2007; Kaufmann 
et al., 2004). 
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In the clinical trial conducted by Kaufman (Kaufmann et al., 2004), 18 psoriasis patients 
were enrolled in four dose groups: 0.1, 0.3, 1.0 and 5.0 mg per kg to assess the clinical 
response and the safety of a single intravenous administration of ustekinumab. At week 12, 
PASI 75 was reached in 25, 50, 60 and 100% of patients respectively. In patients responding 
to ustekinumab treatment, the expression of pro-inflammatory cytokines and chemokines 
IFN-, CXCL-8, CCR2, TNF-, IL-12p40 and IL-23p19 subunits was decreased, compared 
with baseline levels (Reddy et al., 2007; Toichi et al., 2006). 
In a second double-blind, placebo-controlled study, patients were randomized to receive 
either a single subcutaneous injection of 0.27, 0.675, 1.35 or 2.7 mg·kg-1 ustekinumab or 
placebo (A. B. Gottlieb et al., 2007). For a second time, patients treated with ustekinumab 
showed a dose-dependent improvement of their psoriasis. PASI 75 was achieved in 60% of 
the 0.27 mg·kg-1 group, 100% in the 0.675 mg·kg-1 group, 50% in the 1.35 mg·kg-1 group and 
100% in the 2.7 mg·kg-1 group, but in none of the patients receiving placebo during the 
whole study period. 
Krueger (G. G. Krueger et al., 2007) evaluated in a double-blind, placebo controlled trial, 
four subcutaneous dosing regimens of ustekinumab in patients with psoriasis; 320 patients 
were randomized to receive one of the following treatment regimens: one 45-mg dose, one 
90-mg dose, four weekly 45-mg doses and four weekly 90-mg doses of ustekinumab or 
placebo. The primary endpoint of the study was a 75% improvement in the PASI at week 12. 
PASI 75 was achieved in 52% of patients receiving ustekinumab 45 mg, in 59% receiving 
ustekinumab 90 mg, in 67% receiving four weekly 45-mg doses and in 81% of patients 
receiving four weekly 90-mg doses, whereas only 2% of patients in the placebo group 
achieved a PASI 75. 
Another  placebo-controlled double blind randomized crossover study was conducted to 
evaluate the efficacy of ustekinumab in 146 patients suffering from PsA (A. Gottlieb et al., 
2009). Patients were either randomized to receive ustekinumab 90 or 63 mg every week for 4 
weeks (weeks 0–3) followed by placebo at weeks 12 and 16 (76 patients, group 1) or placebo 
(weeks 0–3) and ustekinumab (63 mg) at weeks 12 and 16 (70 patients, group 2). ACR 20 at 
week 12 (taken as the primary endpoint of the study) was achieved by 42% of patients in 
group 1 and by 14% in group 2 (P = 0.0002). Significantly more patients in group 1 achieved 
PASI 75 compared with group 2 in week 12 (52% vs. 5%, P < 0.0001). However, one should 
note that the dosages of ustekinumab used in the study were higher (90 and 63 mg, 
respectively) than those recommended for patients of normal weight (45 mg) with psoriasis 
(Leonardi et al., 2008). 
In conclusion, we report the results of  the two double-blind, placebo-controlled phase III 
studies (Phoenix 1 and Phoenix 2) in patients with psoriasis were performed parallel in USA 
and Europe. Primary outcome in both studies was PASI 75 at week 12 (Leonardi et al., 2008; 
211,). 766 patients of  Phoenix 1 trial were randomly assigned to receive either ustekinumab 
45 mg or 90 mg at weeks 0 and 4 and afterwards every 12 weeks or placebo at weeks 0 and 4 
and to cross over at week 12 to ustekinumab (Leonardi et al., 2008; Papp et al., 2008). 
Furthermore, patients initially receiving ustekinumab and reaching a PASI 75 at weeks 28 
and 40 were re-randomized at week 40 to either continue therapy with ustekinumab or to 
withdrawal of the study drug until loss of response. Significantly more patients in both 
ustekinumab groups (45 and 90 mg) received a PASI 75 at week 12 compared with the 
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placebo group. Patients receiving maintenance therapy up to week 76 significantly better 
sustained PASI 75 than patients randomized to the drug withdrawal group (P < 0.0001).  
The design of the Phoenix 2 study closely resembles that of the Phoenix 1 trial (Papp et al., 
2008). Of the 1230 patients, 409 patients were randomized to receive ustekinumab 45 mg, 
411 to receive ustekinumab 90 mg and 410 to receive placebo at weeks 0 and 4. The efficacy 
analysis at week 12 revealed the following results for the three groups. The primary 
endpoint was achieved in 66.7% of the ustekinumab 45-mg group, 75.7% of the ustekinumab 
90 mg and 3.7% of the placebo group (P < 0.0001 for both ustekinumab 45 and 90 mg vs. 
placebo). 
Quality of life was significantly improved in the patients treated with ustekinumab 
compared with the placebo groups (P < 0.0001) in both Phoenix trials. Patients randomized 
to maintenance therapy in the Phoenix 1 study were able to sustain improved DLQI scores 
until the end of the study, whereas in patients withdrawn from the study drug, the DLQI 
deteriorated again (Leonardi et al., 2008; Papp et al., 2008). 
In a randomized active-controlled, parallel three-arm trial (ACCEPT trial), ustekinumab (45 
and 90 mg, respectively) was compared versus the anti-TNF- etanercept (50 mg twice 
weekly) (C. E. M. Griffiths et al., 2008). The primary endpoint of the study was PASI 75 at 
week 12. 903 patients were randomized in 3 treatment-arms as follows: 347 patients received 
etanercept 50 mg subcutaneously twice weekly, 209 patients received ustekinumab 45 mg 
subcutaneously at weeks 0 and 4, and 347 patients received ustekinumab 90 mg 
subcutaneously at weeks 0 and 4. PASI 75 at week 12 was achieved by 56.8% of patients in 
the etanercept group, by 67.5% in the ustekinumab 45-mg group and 73.8% in the 
ustekinumab 90-mg group. A greater proportion of patients receiving ustekinumab (45 or 90 
mg) achieved PASI 75 when compared with the etanercept group (P = 0.012 for 
ustekinumab 45 mg, P < 0.001 for ustekinumab 90 mg). Interestingly, PASI 75 values at 
week 12 in patients receiving etanercept were better than those published in previous 
studies (Leonardi et al., 2008; Papp et al., 2008). 
The table 4 resume the major results obtained using the briakinumab and ustekinumab in 
psoriasis treatments. 
About the major side effects of treatments with ustekinumab; in the phase I studies, no 
serious adverse events were reported (A. B. Gottlieb et al., 2007; Kaufmann et al., 2004). 
Adverse events included headaches, abdominal pain and common cold symptoms. Adverse 
events were comparable in the phase II studies between ustekinumab and placebo groups 
(79% vs. 72%) (G. G. Krueger et al., 2007). Serious adverse events in patients treated with 
ustekinumab were infections (2 patients), myocardial infarctions (2 patients), a 
cerebrovascular accident (1 patient), non-melanoma skin cancer (2 patients) and prostate 
cancer (1 patient). 
In the placebo group, one patient had a basal cell carcinoma and one patient experienced 
aggravation of his psoriasis requiring hospitalization. In the PsA trial conducted by Gottlieb, 
the following serious adverse events were reported in the ustekinumab groups: syncope (1 
patient), respiratory tract infection (1 patient), haemorrhage (1 patient), stroke (1 patient), 
congestive heart failure/myocardial infarction/hypertension (1 patient), chest pain (1 
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patient), gastric ulcer haemorrhage/abdominal pain/back pain (1 patient) and basal cell 
carcinoma (1 patient) respectively (A. Gottlieb et al., 2009). Two serious infections occurred 
during the placebo-controlled phase of the two large phase III trials: one case of cellulitis 
and one case of herpes zoster (both in the ustekinumab 90-mg group) (Ding et al., 2008; 
Ortonne et al., 2007). 
During the placebo-controlled phase of the Phoenix 2 study, a squamous cell carcinoma in a 
patient in the placebo group and a basal cell carcinoma in a patient in the ustekinumab 90-
mg group were observed (Ding et al., 2008). Comparing patients on maintenance therapy 
with patients randomized to the withdrawal group in Phoenix 1 study did not reveal an 
increased infection rate between the two groups (Ortonne et al., 2007).  
 
Therapy Disease Trial Type Treatment  (n° 
of patients)
Major 
Results
Reference 
Briakinumab Psoriasis 12-week 
RDBPC 
B 200 mg x 1 (30)
B 100 mg eow (3)
B 200 mg x 4 (30)
B 200 mg eow 
(30) 
B 200 mg weekly 
(30) 
Placebo (30) 
PASI 75 at 
week 12: 63 
PASI 75 at 
week 12: 93 
PASI 75 at 
week 12: 90 
PASI 75 at 
week 12: 93 
PASI 75 at 
week 12: 90 
PASI 75 at 
week 12: 1 
Kimball et al., 
2008 
Arch Dermatol 
144: 200–207. 
 
Ustekinumab  
PHOENIX 1 
Psoriasis RDBPC 
U 45 mg (255)
U 90 mg (256) 
Placebo (255 
PASI 75 at 
week 12: 67.1
PASI 75 at 
week 12: 66.4
PASI 75 at 
week 12: 3.1 
Leonardi et al., 
2008 
Lancet 371: 
1665 -1674. 
 
Ustekinumab  
PHOENIX 2 
Psoriasis RDBPC 
U 45 mg (409)
U 90 mg (411) 
Placebo (410) 
PASI 75 at 
week 12: 66.7
PASI 75 at 
week 12: 75.7
PASI 75 at 
week 12: 3.7
Papp et al.,  
2008 
Lancet 371: 
1675–1684. 
 
Ustekinumab  
ACCEPT 
Psoriasis  RDBPC 
U 45 mg (209)
U 90 mg (347) 
E 2 X 50 mg 
(347) 
PASI 75 at 
week 12: 67.5
PASI 75 at 
week 12: 73.8
PASI 75 at 
week 12: 56.8
Griffiths et al., 
2010 
N Engl J Med. 
362: 118-128 
 
B = Briakinumab;  E = Etanercept; U = Ustekinumab; RDBPC = Randomized Double-Blind Placebo 
Controlled Trial 
Table 4. Efficacy of anti- IL-12/IL-23 in the psoriasis cure  
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However, as Th1 and Th17 blockade by ustekinumab might impair cell-mediated immunity, 
normal KCs host immunity and defence against malignancies, close monitoring in patients 
on long-term treatment with ustekinumab seems to be appropriate (O’Neill & Kalb, 2009). In 
the ACCEPT trial, serious adverse events have been observed in 1.2% of patients in the 
etanercept group, 1.9% in the ustekinumab 45-mg group and 1.2% of patients in the 
ustekinumab 90 mg group respectively. These included 4 patients in each treatment group: 
etanercept group: abdominal pain, bacterial meningitis, nephrolithiasis, rotator cuff 
syndrome; 45-mg ustekinumab group: alcoholic pancreatitis, chest pain/hypertension, 
psychotic disorder, breast cancer; ustekinumab 90-mg group: urosepsis/renal failure, 
uveitis, appendicitis and gastroenteritis from food poisoning (C. E. M. Griffiths et al., 2008). 
8. Conclusion 
Based on  a large series of studies, that we discuss in the different paragraphs, current 
evidence indicates the importance of T cells during psoriasis pathogenesis and demonstre 
that T cell expansion precedes the development of typical psoriatic changes; the more 
reasonable conclusion is that psoriasis is the outcome of an inappropriate T cell-based 
activation event, together with a defect in KCs, whose combination results in the full 
psoriatic phenotype. 
Once recognized the primary role of T cells in  psoriasis pathogenesis, several biological 
therapies have been developed and proposed to counteract immune T response. These 
treatments consist  in blocking the actions of several T cell cytokines that play a key role in 
sustain the pathogenesis of early and late events of psoriasis, e.g. anti-IL23 and anti-TNF-. 
So far, considering published data from the clinical trials, the new biological agents have 
been shown to be efficient treatment options for patients suffering from psoriasis and the 
major comorbidities disease-associated, primarily PsA. 
These new biological agents  seem to have proven a good risk/benefit ratio. As psoriasis is 
considered a life-long disease and no causal therapy for the disease is yet available, long-
term studies on safe and efficacious treatments are needed and are of major importance. 
Taking into account the possibility that uncommon adverse events or events occurring 
during long-term exposure to these drugs might emerge in the future (e.g. the development 
of progressive multifocal leukoencephalopathy in long-term patients treated with 
efalizumab), vigilant and careful post-marketing surveillance in patients treated with 
biological agents is strongly recommended. 
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